- Home
- MLP vs ATXS Comparison
MLP vs ATXS Comparison
Compare MLP & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLP
- ATXS
- Stock Information
- Founded
- MLP 1909
- ATXS 2008
- Country
- MLP United States
- ATXS United States
- Employees
- MLP N/A
- ATXS N/A
- Industry
- MLP Real Estate
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- MLP Finance
- ATXS Health Care
- Exchange
- MLP Nasdaq
- ATXS Nasdaq
- Market Cap
- MLP 512.1M
- ATXS 584.1M
- IPO Year
- MLP 1972
- ATXS 2015
- Fundamental
- Price
- MLP $22.37
- ATXS $9.42
- Analyst Decision
- MLP
- ATXS Strong Buy
- Analyst Count
- MLP 0
- ATXS 5
- Target Price
- MLP N/A
- ATXS $28.00
- AVG Volume (30 Days)
- MLP 20.1K
- ATXS 380.1K
- Earning Date
- MLP 11-14-2024
- ATXS 11-13-2024
- Dividend Yield
- MLP N/A
- ATXS N/A
- EPS Growth
- MLP N/A
- ATXS N/A
- EPS
- MLP N/A
- ATXS N/A
- Revenue
- MLP $12,196,000.00
- ATXS N/A
- Revenue This Year
- MLP N/A
- ATXS N/A
- Revenue Next Year
- MLP N/A
- ATXS N/A
- P/E Ratio
- MLP N/A
- ATXS N/A
- Revenue Growth
- MLP 34.84
- ATXS N/A
- 52 Week Low
- MLP $15.57
- ATXS $6.58
- 52 Week High
- MLP $26.46
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- MLP 46.61
- ATXS 40.70
- Support Level
- MLP $21.11
- ATXS $9.23
- Resistance Level
- MLP $23.41
- ATXS $9.63
- Average True Range (ATR)
- MLP 0.69
- ATXS 0.57
- MACD
- MLP 0.03
- ATXS -0.00
- Stochastic Oscillator
- MLP 54.78
- ATXS 20.50
About MLP Maui Land & Pineapple Company Inc.
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales: , which includes land planning and entitlement, development, and sales activities.; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.